About METACLIPSE THERAPEUTICS CORP
Metaclipse Therapeutics is a biotechnology company focused on developing membrane-bound biological adjuvants for immunotherapies targeting cancer and infectious diseases. The company is advancing personalized immunotherapy platforms such as Membrex™ and VaxRex™, with clinical trials expected to begin in 2025.
Development of membrane-bound biological adjuvants for immunotherapiesCreation of personalized cancer immunotherapies using patient-specific tumor antigensDesign of virus-like particle (VLP) vaccines for infectious disease preventionPreclinical and clinical development of immunotherapies for cancers including triple negative breast cancer and head and neck squamous cell carcinomaRapid, cost-effective manufacturing of immunotherapies
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| SBIR CONCEPT AWARD FOR DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENTION OF | Department of Health and Human Services | $355K | |
| Federal contract award | Department of Health and Human Services | $4.1M |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to METACLIPSE THERAPEUTICS CORP right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.